<DOC>
	<DOCNO>NCT01436227</DOCNO>
	<brief_summary>The goal clinical research study learn pazopanib help control VHL . The safety drug also study . Pazopanib design block growth blood vessel supply nutrient need tumor growth . This may prevent slow growth cancer cell .</brief_summary>
	<brief_title>Pazopanib Von Hippel-Lindau ( VHL ) Syndrome</brief_title>
	<detailed_description>Study Groups Study Drug Administration : If find eligible take part study , take pazopanib mouth 1 time every day , time day , least 1 hour 2 hour meal . If side effect drug , tell study doctor right away . The study doctor may lower dose keep dose level . Each study cycle 4 week . Study Visits : On Day 1 Cycle 1 : - Your medical history record . - You physical exam , include measurement vital sign weight . - You ask drug treatment may receive . - Your performance status record . Every 2 week ( first 8 week ) every cycle , blood ( 3 teaspoon ) draw routine test . Every 12 week ( +/-7 day ) : - Your medical history record . - You physical exam , include measurement vital sign weight . - Your performance status record . - You ask drug treatment may receive side effect . At end Cycles 3 6 every 12 week : - You CT scan MRI scan check status disease . - If doctor think need , eye exam . Length Study : You may receive treatment study 24 week ( 6 cycle ) . If doctor think benefit , may continue study . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete end-of-study visit follow-up . Early Withdrawal/End-of-Study Visit : If leave study reason , follow test perform . - You physical exam . - Your performance status record . - You ask drug treatment may receive side effect . - Blood ( 3 teaspoon ) draw routine test . - You CT scan MRI scan check status disease . - If doctor think need , eye exam . Long-Term Follow-up : After off-study , study staff collect information either check medical record call . If call , 30 day last dose every 3 month 24 week . Each call last 5 minute . This investigational study . Pazopanib FDA approve commercially available kidney cancer . Its use treat VHL investigational . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<criteria>1 . Subjects must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment follow . Procedures conduct part subject 's routine clinical management ( e.g. , blood count , image study ) obtain prior signing inform consent may utilize screen baseline purpose provide procedure conduct specify protocol . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 3 . Genetically confirm diagnosis VHL measurable disease consistent clinical diagnosis VHL . ( Please refer criterion # 5 ) 4 . Measurable disease criterion : At least one measurable VHL related lesion , undergo surveillance , patient immediate risk need intervention lesion . Biopsy require give known likely etiology natural history set positive genetic test . . ) Brain : asymptomatic hemangioblastoma , &gt; /= 0.5 cm ; b ) Spine : asymptomatic hemangioblastoma , &gt; /= 0.5 cm ; c ) Renal : solid mass suspicious RCC &gt; /= 1 cm cystic mass ( Bosniak 34 ) &gt; /= 1 cm . ; ) Pancreas : solid mass &gt; /= 1cm &lt; /= 3 cm suspicious neuroendocrine tumor , neuroendocrine tumor &gt; 3 cm consider operable . ; e ) Eye : asymptomatic peripapillary and/or macular hemangioblastoma , size ; f ) Adrenal : asymptomatic control pheochromocytoma great 1cm size 5 . Patients may receive prior VHLrelated systemic therapy , provide within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib . 6 . Adequate organ system function define : ) Absolute neutrophil count ( ANC ) &gt; /= 1.5 X 10^9/L ; b ) Hemoglobin &gt; /= 9 g/dL ( 5.6 mmol/L ) ; c ) Platelets &gt; /= 100 X 10^9/L ; ) Prothrombin time ( PT ) international normalize ratio ( INR ) &lt; /= 1.2 X ULN ; e ) Activated partial thromboplastin time ( aPTT ) &lt; /= 1.2 X ULN ; f ) Total bilirubin &lt; /= 1.5 X ULN ; g ) Alanine amino transferase ( ALT ) Aspartate aminotransferase ( AST ) &lt; /= 2.0 X ULN ; h ) Serum creatinine &lt; /= 2.0 mg/dL ( 133 Âµmol/L ) Or , &gt; 2.0 mg/dL : Calculated creatinine clearance ( ClCR ) ( appropriate appendix ) &gt; /= 50 mL/min ; ) Urine Protein Creatinine Ratio ( UPC ; appropriate appendix ) &lt; 1 7 . A female eligible enter participate study : Nonchildbearing potential include ) female surgical procedure render incapable become pregnant . ; b ) Subjects use hormone replacement therapy ( HRT ) must experience total cessation menses &gt; /= 1 year great 45 year age , OR , questionable case , follicle stimulate hormone ( FSH ) value &gt; 40 mIU/mL estradiol value &lt; 40 pg/mL ( &lt; 140 pmol/L ) . ; c ) Subjects use HRT must experience total cessation menses &gt; /= 1 year great 45 year age OR document evidence menopause base FSH estradiol concentration prior initiation HRT ; Childbearing potential , include female negative serum pregnancy test within 2 week prior first dose study treatment , preferably close first dose possible , agree use adequate contraception . 8 . # 8 Cont . ) GSK acceptable contraceptive method , use consistently accordance product label instruction physician , follow : ) Complete abstinence sexual intercourse 14 day exposure investigational product , dose period , least 21 day last dose investigational product . b ) Oral contraceptive c ) Injectable progestogen . ) Implants levonorgestrel . e ) Estrogenic vaginal ring f ) Percutaneous contraceptive patch g ) Intrauterine device ( IUD ) h ) Male partner sterilization ) Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film/cream/suppository ) . ; Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . 1 . Prior malignancy . Note : Subjects another non VHL related malignancy diseasefree 2 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . 2 . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include , limited : ) Active peptic ulcer disease ; b ) Known intraluminal metastatic lesion/s risk bleeding ; c ) Inflammatory bowel disease ( e.g . ulcerative colitis , Chrohn 's disease ) , gastrointestinal condition increase risk perforation ; ) History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment . 3 . Clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : ) Malabsorption syndrome ; b ) Major resection stomach small bowel . 4 . Presence uncontrolled infection 5 . Corrected QT interval ( QTc ) &gt; 480 msec use Bazett 's formula 6 . History one follow cardiovascular condition within past 6 month : ) Cardiac angioplasty stenting ; b ) Myocardial infarction ; c ) Unstable angina ; ) Coronary artery bypass graft surgery ; e ) Symptomatic peripheral vascular disease ; f ) Class III IV congestive heart failure , define New York Heart Association ( NYHA ) 7 . Poorly control hypertension [ define systolic blood pressure ( SBP ) &gt; /= 140 mmHg diastolic blood pressure ( DBP ) &gt; /= 90mmHg ] . Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . BP must reassess two occasion separate minimum 1 hour ; occasion , mean ( 3 reading ) SBP / DBP value BP assessment must &lt; 140/90 mmHg order subject eligible study ( see Section 3.0. detail BP control reassessment prior study enrollment ) . 8 . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible 9 . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major ) . 10 . Evidence active bleeding bleed diathesis 11 . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . 12 . Unable unwilling discontinue use prohibit medication list least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study . 13 . Treatment follow anticancer therapy : ) radiation therapy , surgery tumor embolization within 14 day prior first dose pazopanib OR ; b ) chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib 14 . Any ongoing toxicity prior investigational therapy &gt; Grade 1 and/or progress severity , except alopecia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Von Hippel-Lindau Syndrome</keyword>
	<keyword>VHL</keyword>
	<keyword>Von Hippel-Lindau related lesion</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>GW786034</keyword>
</DOC>